Single-domain antibodies for allergen detection
Quantitative BioSciences, Inc. offers a service for developing single-domain antibodies (sdAbs) for allergen detection through library screening. Ideal for scenarios lacking commercial antibodies, it provides custom solutions with high sensitivity in a 4-6 week timeframe.
Overview
Quantitative BioSciences, Inc. presents a specialized service for the development of single-domain antibodies (sdAbs) tailored for allergen detection. This solution addresses the need for high-sensitivity antibodies when commercial options are unavailable. By leveraging our extensive library, we can screen for sdAbs against any specific allergen of interest, providing a customized and efficient alternative to traditional antibody development methods.
Technical specifications
Our service utilizes a comprehensive single-domain antibody library capable of generating sdAbs for virtually any target with high sensitivity. The typical process involves screening this library to identify sdAbs that bind to the desired allergen target. This method is not only cost-effective compared to traditional immunization approaches but also significantly reduces the development time, completing within 4-6 weeks per target at a cost of approximately $10,000.
Technology readiness level
The current technology readiness level of this service is 3, indicating that the core concept has been validated in a laboratory setting. Further development and validation are planned to enhance its applicability and reliability in broader contexts.
About Quantitative BioSciences, Inc.
Quantitative BioSciences, Inc. (QBI) is a biotechnology company that integrates bioengineering, synthetic biology, and bioinformatics to develop custom biosensing and immunoassay solutions. Founded in 2010, the company built the Qube platform, an at-line, autonomous sensing system designed for continuous, multiplexed, and quantitative monitoring of various analytes, including proteins, pathogens, chemicals, and environmental contaminants. Their technology utilizes proprietary synthetic libraries for rapid VHH (single-domain antibody) discovery, allowing for the customization of sensors to specific targets. The company combines microfluidics, machine learning, and advanced optics to translate biological signals into actionable data, providing alternatives to traditional, sporadic laboratory sampling methods.
QBI serves clients across the life sciences, pharmaceutical, water treatment, and environmental monitoring sectors by providing tools for process control, real-time quality assurance, and early warning systems. Their technology has been validated through numerous R&D projects supported by federal agencies including the NIH, DOE, DARPA, IARPA, USDA, EPA, and NOAA. By deploying these robust, field-deployable platforms, QBI helps partners reduce labor, automate complex monitoring workflows, and improve decision-making in both industrial and environmental settings. The company frequently collaborates with academic and commercial partners to demonstrate the utility and field robustness of its sensing technologies.
delivered to your inbox.